CAeditome Logo

Home

Download

Statistics

Landscape

Help

Contact
Center for Computational Systems Medicine
Soverview

1. Gene summary of enriched editing regions

Soverview

2. Tumor-specific enriched editing regions

Comparison of enriched editing regions between tumor and normal.

Correlation of enriched editing regions with tumor stages.

Associations of enriched editing regions with cancer survival.

Soverview

3. Enriched editing regions and immune related genes

Soverview

4. Enriched editing regions and immune related splicing

Soverview

5. Enriched editing regions and immune infiltration

Soverview

6. Enriched editing regions and immune gene sets

Correlation of enriched editing regions with epithelial-mesenchymal transition.

Correlations of enriched editing regions with hypoxic.

Associations of enriched editing regions with hallmark gene sets from MSigDB.

Soverview

7. Enriched editing regions and drugs

Correlations between enriched editing regions and drug sensitivity.

Enriched editing regions targeted by drugs from DrugBank database.

Editing gene: OPA3 (ImmuneEditome ID:80207)

1. Gene summary of enriched editing regions for OPA3

check button Gene summary
Gene informationGene symbol

OPA3

Gene ID

80207

GeneSynonymsMGA3
GeneCytomap

19q13.32

GeneTypeprotein-coding
GeneDescriptionoptic atrophy 3 protein|3-methylglutaconic aciduria type III|OPA3 outer mitochondrial membrane lipid metabolism regulator|Optic atrophy 3 (Iraqi-Jewish 'optic atrophy plus')|optic atrophy 3 (autosomal recessive, with chorea and spastic paraplegia)
GeneModificationdate20230517
UniprotIDQ9H6K4;B4DK77
PubMed ID

check buttonUCSC image.
all structure

check buttonLocations of each EERs.
EERENSTENSGGeneNameRegionRepeatdsRNA structure
chr19:45546893-45548018:-ENST00000263275.4ENSG00000125741.4OPA3UTR3LTR16A,MER58A,L2b,AluSp,AluSzchr19:45546893-45548018:-.alignment
chr19:45548988-45551287:-ENST00000263275.4ENSG00000125741.4OPA3UTR3MIR3,AluSx1,AluSz6,AluSx,AluJbchr19:45548988-45551287:-.alignment
chr19:45552272-45552892:-ENST00000263275.4ENSG00000125741.4OPA3UTR3AluSz,AluSx1,AluSpchr19:45552272-45552892:-.alignment
chr19:45552272-45552892:-ENST00000544371.1ENSG00000125741.4OPA3UTR3AluSz,AluSx1,AluSpchr19:45552272-45552892:-.alignment


Top

2. Tumor-specific enriched editing regions for OPA3


all structure

check buttonComparison of enriched editing regions between tumor and normal.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypePBoxplot
chr19:45548988-45551287:-COADEER6.4881e-06image
ENSG00000125741.4,OPA3COADEAG2.8334e-06image
chr19:45548988-45551287:-LIHCEER7.9617e-03image
ENSG00000125741.4,OPA3LIHCEAG7.0178e-03image
chr19:45548988-45551287:-LUSCEER2.3151e-06image
ENSG00000125741.4,OPA3LUSCEAG8.1932e-07image
chr19:45548988-45551287:-PRADEER4.9061e-02image
ENSG00000125741.4,OPA3PRADEAG3.3568e-02image
chr19:45548988-45551287:-THCAEER8.7454e-06image
ENSG00000125741.4,OPA3THCAEAG2.4123e-05image
chr19:45548988-45551287:-UCECEER2.2134e-02image
ENSG00000125741.4,OPA3UCECEAG2.8805e-02image


Top

check buttonCorrelation of enriched editing regions with tumor stages.
* AnovaP<0.05, Pearson P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes, Path: Pathological stage, Cli: Clinical stage.
* Only shows the most significant correlation result of EERs/EAGs with either pathological stage or clinical stage according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeStageTypeAnovaPPRBoxplot
chr19:45548988-45551287:-ESCAPathEER4.6524e-023.5658e-020.1765image
chr19:45548988-45551287:-STADPathEER4.2221e-024.3530e-02-0.1104image
ENSG00000125741.4,OPA3STADPathEAG1.4980e-021.0428e-02-0.1394image


Top

check button Associations of enriched editing regions with cancer survival.
* Pkm<0.05 and Pcox<0.05.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypeIDPkmPcox_continuousHR_continuousKMPlot
ENSG00000125741.4,OPA3ESCAEAG2.7845e-024.4582e-022.6078e+03image
chr19:45548988-45551287:-GBMEER3.4062e-024.0248e-021.0662e-02image

Top

3. Enriched editing regions and immune related genes for OPA3


all structure

check button Enriched editing regions and immune related genes.
* First, the associations between enriched editing regions and genes were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the gene relationships with immune were tested by three analyses: whether the gene is an immune gene (InnateDB、Immport、Immunome、Immunogenetic Related Information Source (IRIS)), whether the gene is associated with immune infiltration and whether the gene is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of genes with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeGenebetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
chr19:45548988-45551287:-OVEERENSG00000215845,TSTD10.37981.0490e-071.9374e-120.4017imageNCSTF2T;DDX54;DHX9;EIF4A3;ELAVL1;FAM120A;FBL;FUS;HNRNPA1;HNRNPU;IGF2BP1;NOP56;NOP58;PTBP1;RBFOX2;TARDBP;U2AF2NAMacrophages_M0GSVA_HALLMARK_MITOTIC_SPINDLE
chr19:45548988-45551287:-OVEERENSG00000182117,NOP100.37621.4924e-072.5777e-150.4464imageNAUH;CSTF2T;DDX54;DGCR8;EIF4A3;EIF4G2;ELAVL1;FAM120A;FBL;FUS;FXR1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;ILF3;KHDRBS1;LIN28B;LSM11;NONO;NOP56;NOP58;PTBP1;RBM10;RBM22;SAFB2;SLTM;SRSF7;TAF15;TARDBP;U2AF2;YWHAGNAT_cells_CD8GSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATION
chr19:45548988-45551287:-OVEERENSG00000179085,DPM30.34183.6012e-066.0244e-140.4260imageNADAR;AUH;CSTF2T;DDX54;DGCR8;EIF4A3;ELAVL1;FAM120A;FBL;FUS;FXR1;HNRNPA1;HNRNPK;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;ILF3;KHDRBS1;LIN28B;LSM11;NONO;NOP58;RBFOX2;RBM10;RBM22;SAFB2;SLTM;TAF15;TARDBP;U2AF2NAB_cells_memoryGSVA_HALLMARK_HEDGEHOG_SIGNALING
chr19:45548988-45551287:-OVEERENSG00000260552,RP11-49I11.10.29946.7819e-051.7117e-120.4026imageNDGCR8;EIF4A3;FAM120A;FBL;FUS;IGF2BP2;NONO;PTBP1;RBFOX2;SRSF7;U2AF2NAT_cells_gamma_deltaGSVA_HALLMARK_HEDGEHOG_SIGNALING
chr19:45548988-45551287:-TGCTEERENSG00000137876,RSL24D10.40032.7023e-051.6138e-080.4358imageNAUH;CELF2;CSTF2T;DDX54;DGCR8;EIF4A3;EIF4G2;ELAVL1;FAM120A;FBL;FUS;FXR1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;ILF3;KHDRBS1;KHSRP;LIN28B;LSM11;NONO;NOP56;NOP58;PTBP1;RBFOX2;RBM10;RBM22;SAFB2;SLTM;SRSF7;TAF15;TARDBP;U2AF2;YWHAGNAMacrophages_M2GSVA_HALLMARK_APICAL_JUNCTION
chr19:45548988-45551287:-TGCTEERENSG00000169714,CNBP0.39334.5370e-051.7015e-070.4064imageNADAR;AUH;CELF2;CSTF2T;DDX54;DGCR8;DHX9;EIF4A3;EIF4G2;ELAVL1;FAM120A;FBL;FUS;FXR1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;ILF3;KHDRBS1;KHSRP;LIN28B;LSM11;NONO;NOP56;NOP58;PTBP1;RBFOX2;RBM10;RBM22;SAFB2;SLTM;SRSF7;TAF15;TARDBP;U2AF2;VIM;YWHAGNAMacrophages_M2GSVA_HALLMARK_APICAL_JUNCTION
chr19:45548988-45551287:-TGCTEERENSG00000273284,RP11-888D10.40.34664.3540e-041.7776e-090.4610imageNCSTF2T;DDX54;ELAVL1;FAM120A;FBL;IGF2BP1;IGF2BP2;NOP56;NOP58;SLTM;U2AF2NAMacrophages_M2GSVA_HALLMARK_ANGIOGENESIS
chr19:45548988-45551287:-TGCTEERENSG00000231747,AC079922.20.30942.6287e-038.4233e-090.4434imageNNNAMacrophages_M2GSVA_HALLMARK_TGF_BETA_SIGNALING
chr19:45548988-45551287:-TGCTEERENSG00000277662,RP11-74J13.90.25871.1405e-022.1478e-080.4324imageNFBL;IGF2BP2;NOP56NAMacrophages_M2GSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALING
chr19:45548988-45551287:-TGCTEERENSG00000275191,RP11-36I17.20.25231.2721e-021.1884e-110.5117imageNDDX54;EIF4A3;TAF15;U2AF2NAMacrophages_M2GSVA_HALLMARK_TGF_BETA_SIGNALING

More results



Top

4. Enriched editing regions and immune related splicing for OPA3


all structure

check button Enriched editing regions and immune related splicing.
* First, the associations between enriched editing regions and splicing events were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the splicing relationships with immune were tested by three analyses: whether the splicing event locates in an immune gene (InnateDB、Immport, Immunome and Immunogenetic Related Information Source (IRIS)), whether the splicing event is associated with immune infiltration and whether the splicing event is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of splicing events with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeSplicingTypeSplicingGeneSplicingChrSplicingPositionbetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
ENSG00000125741.4,OPA3
OVEAGMEXENSG00000197070.9chr9137614298:137614475:137614558:137614898:137614922:137615000:137615073:137615358-0.31446.4623e-051.3934e-12-0.4041imageNACIN1;ADAR;AIFM1;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHSRP;LARP4B;LIN28;LIN28B;LSM11;MOV10;MSI1;MSI2;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RNF219;SAFB2;SF3A3;SF3B4;SLBP;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YWHAG;ZC3H7B;ZNF184NAB_cells_memoryGSVA_HALLMARK_MITOTIC_SPINDLE
chr19:45548988-45551287:-
OVEERIRENSG00000118579.7chr417623600:17625845:17628005:17628170-0.28461.2541e-043.0974e-11-0.4040imageNADAR;AUH;CELF2;CSTF2T;DDX54;DGCR8;DHX9;EIF4A3;EIF4G2;ELAVL1;FAM120A;FBL;FUS;FXR1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;ILF3;KHDRBS1;KHSRP;LIN28B;LSM11;NONO;NOP56;NOP58;PTBP1;RBFOX2;RBM10;RBM22;SAFB2;SLTM;SRSF7;TAF15;TARDBP;U2AF2;VIM;YWHAGNAT_cells_CD8GSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALING
ENSG00000125741.4,OPA3
OVEAGMEXENSG00000090861.11chr1670261043:70261157:70262345:70262524:70265537:70265662:70267658:702677960.30042.4450e-042.9313e-130.4152imageNACIN1;ADAR;AIFM1;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHSRP;LARP4B;LIN28;LIN28A;LIN28B;LSM11;MBNL2;METTL3;MOV10;MSI1;MSI2;NCBP3;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;QKI;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM47;RNF219;SAFB2;SF3A3;SF3B4;SLBP;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;WTAP;XRN2;YTHDC1;YTHDF1;YWHAG;ZC3H7B;ZNF184NAMacrophages_M2GSVA_HALLMARK_HEDGEHOG_SIGNALING
ENSG00000125741.4,OPA3
OVEAGMEXENSG00000171853.11chr23460300:3460336:3465596:3466393:3477694:3477795:3478845:3478871-0.34767.1014e-062.1864e-12-0.4009imageNACIN1;ADAR;AIFM1;AUH;BCCIP;BUD13;CELF2;CNBP;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHSRP;LIN28;LIN28A;LIN28B;LSM11;MBNL2;METTL3;MOV10;MSI1;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;QKI;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM47;RNF219;SAFB2;SF3A3;SF3B4;SLBP;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;WTAP;XRN2;YTHDC1;YTHDF1;YWHAG;ZNF184NAB_cells_memoryGSVA_HALLMARK_MITOTIC_SPINDLE
ENSG00000125741.4,OPA3
OVEAGMEXENSG00000108821.9chr1750187014:50187122:50187483:50187537:50196154:50196199:50196313:501963670.44097.4113e-104.3294e-130.4124imageNACIN1;ADAR;CNBP;CSTF2T;DDX54;DGCR8;DKC1;EIF4A3;ELAVL1;ELAVL3;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;HNRNPA2B1;HNRNPC;HNRNPM;HNRNPU;IGF2BP1;IGF2BP2;IGF2BP3;LIN28;LIN28A;LIN28B;LSM11;MBNL2;METTL3;MOV10;MSI1;NCBP3;NOP56;NOP58;PCBP2;PRPF8;PTBP1;RBFOX2;RBM10;SMNDC1;SND1;SRSF1;SRSF3;TAF15;TARDBP;TIA1;TIAL1;TROVE2;U2AF1;U2AF2;UPF1;WTAP;YTHDC1;YTHDF1;ZNF184COL1A1B_cells_memoryGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALING
ENSG00000125741.4,OPA3
OVEAGIRENSG00000118579.7chr417623600:17625845:17628005:17628170-0.30801.9720e-053.1263e-13-0.4395imageNACIN1;ADAR;AIFM1;AUH;BCCIP;BUD13;CBX7;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHSRP;LARP4B;LIN28;LIN28A;LIN28B;LSM11;MBNL2;METTL3;MOV10;MSI1;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM47;RNF219;SAFB2;SF3A3;SF3B4;SLBP;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDC1;YTHDF1;YWHAG;ZC3H7B;ZNF184NAT_cells_CD8GSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALING
ENSG00000125741.4,OPA3
OVEAGMEXENSG00000197070.9chr9137614298:137614475:137614558:137614898:137614898:137615000:137615073:137615358-0.32463.0123e-055.5141e-13-0.4107imageNACIN1;ADAR;AIFM1;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHSRP;LARP4B;LIN28;LIN28B;LSM11;MOV10;MSI1;MSI2;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RNF219;SAFB2;SF3A3;SF3B4;SLBP;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YWHAG;ZC3H7B;ZNF184NANK_cells_activatedGSVA_HALLMARK_MITOTIC_SPINDLE
chr19:45548988-45551287:-
TGCTEERIRENSG00000130175.5chr1911449265:11449882:11450428:11450716-0.40833.0497e-045.2473e-08-0.4214imageNADAR;AUH;CSTF2T;DDX54;DGCR8;DHX9;EIF4A3;EIF4G2;ELAVL1;FAM120A;FBL;FUS;FXR1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;ILF3;KHDRBS1;KHSRP;LIN28B;LSM11;NONO;NOP56;NOP58;PTBP1;RBFOX2;RBM10;RBM22;SAFB2;SLTM;SRSF7;TAF15;TARDBP;U2AF2;VIM;YWHAGPRKCSHMacrophages_M2GSVA_HALLMARK_ALLOGRAFT_REJECTION
ENSG00000125741.4,OPA3
TGCTEAGIRENSG00000115392.7chr258159242:58163517:58165723:581658030.30091.6880e-026.8636e-100.4741imageNACIN1;ADAR;AIFM1;AUH;BCCIP;BUD13;CBX7;CELF2;CNBP;CSTF2T;DDX3X;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;ELAVL1;ELAVL3;FAM120A;FBL;FMR1;FUS;FXR2;GTF2F1;HNRNPA1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;LARP4B;LIN28A;LIN28B;LSM11;MBNL2;METTL3;MOV10;MSI1;MSI2;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;QKI;RBFOX2;RBM10;RBM22;RBM47;SF3A3;SF3B4;SLBP;SMNDC1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;YTHDC1;YTHDF1;ZC3H7B;ZNF184FANCLMacrophages_M2GSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALING
chr19:45548988-45551287:-
TGCTEERIRENSG00000166012.10chr1193730193:93730712:93731145:93731216-0.25372.5528e-024.8431e-12-0.5320imageNADAR;AUH;CELF2;CSTF2T;DDX54;DGCR8;DHX9;EIF4A3;EIF4G2;ELAVL1;FAM120A;FBL;FUS;FXR1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;ILF3;KHDRBS1;KHSRP;LIN28B;LSM11;NONO;NOP56;NOP58;PTBP1;RBFOX2;RBM10;RBM22;SAFB2;SLTM;SRSF7;TAF15;TARDBP;U2AF2;VIM;YWHAGNAT_cells_CD4_memory_activatedGSVA_HALLMARK_MITOTIC_SPINDLE

More results



Top

5. Enriched editing regions and immune infiltration for OPA3


all structure

check button Associations of enriched editing regions with immune infiltration.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the fraction of different immune cells according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeIDImmuneCellPRCorrelationPlot
chr19:45548988-45551287:-ACCEERDendritic_cells_activated2.0664e-02-0.2651image
ENSG00000125741.4,OPA3ACCEAGDendritic_cells_activated2.1837e-02-0.2628image
chr19:45548988-45551287:-BLCAEERMacrophages_M29.5268e-030.1295image
ENSG00000125741.4,OPA3BLCAEAGMacrophages_M21.2219e-020.1249image
chr19:45548988-45551287:-BRCAEERMacrophages_M13.5014e-020.0643image
chr19:45552272-45552892:-BRCAEERNK_cells_activated8.1818e-030.1732image
ENSG00000125741.4,OPA3BRCAEAGMast_cells_resting3.8025e-020.0632image
chr19:45548988-45551287:-CESCEERT_cells_CD81.7933e-020.1361image
ENSG00000125741.4,OPA3CESCEAGB_cells_naive2.0355e-02-0.1334image
chr19:45548988-45551287:-CHOLEERMast_cells_activated8.0602e-030.4407image
ENSG00000125741.4,OPA3CHOLEAGMast_cells_activated5.6169e-030.4584image
chr19:45548988-45551287:-COADEERPlasma_cells3.4825e-02-0.1333image
ENSG00000125741.4,OPA3COADEAGPlasma_cells4.0821e-02-0.1292image
chr19:45548988-45551287:-DLBCEERDendritic_cells_resting5.1580e-030.3974image
ENSG00000125741.4,OPA3DLBCEAGDendritic_cells_resting4.4318e-030.4037image
chr19:45548988-45551287:-ESCAEERT_cells_regulatory_(Tregs)5.1545e-03-0.2201image
ENSG00000125741.4,OPA3ESCAEAGT_cells_regulatory_(Tregs)8.4696e-03-0.2075image
chr19:45548988-45551287:-GBMEERPlasma_cells6.5073e-030.2150image
ENSG00000125741.4,OPA3GBMEAGPlasma_cells6.2218e-030.2161image
ENSG00000125741.4,OPA3KICHEAGPlasma_cells2.2248e-020.2832image
chr19:45548988-45551287:-KIRCEERPlasma_cells1.1990e-090.3058image
ENSG00000125741.4,OPA3KIRCEAGPlasma_cells3.3232e-050.2109image
chr19:45548988-45551287:-KIRPEERT_cells_CD86.7495e-040.1999image
ENSG00000125741.4,OPA3KIRPEAGT_cells_CD84.2470e-040.2070image
ENSG00000125741.4,OPA3LAMLEAGMacrophages_M19.6563e-030.2492image
chr19:45548988-45551287:-LGGEERB_cells_naive4.7402e-02-0.0881image
ENSG00000125741.4,OPA3LGGEAGB_cells_naive3.6628e-02-0.0928image
chr19:45548988-45551287:-LIHCEERMacrophages_M11.5448e-050.2238image
ENSG00000125741.4,OPA3LIHCEAGMacrophages_M11.2618e-050.2261image
chr19:45548988-45551287:-LUADEERPlasma_cells1.2929e-020.1132image
ENSG00000125741.4,OPA3LUADEAGEosinophils3.4953e-02-0.0960image
chr19:45548988-45551287:-LUSCEERT_cells_CD4_memory_resting6.2473e-03-0.1234image
ENSG00000125741.4,OPA3LUSCEAGT_cells_CD4_memory_resting7.4103e-03-0.1207image
chr19:45548988-45551287:-OVEERT_cells_CD82.5191e-040.2156image
chr19:45552272-45552892:-OVEERT_cells_CD82.1179e-020.2166image
ENSG00000125741.4,OPA3OVEAGT_cells_CD89.0474e-040.1959image
chr19:45548988-45551287:-PAADEERDendritic_cells_activated1.5524e-020.1817image
ENSG00000125741.4,OPA3PAADEAGDendritic_cells_activated9.5703e-030.1943image
chr19:45548988-45551287:-PCPGEERMacrophages_M07.1218e-040.2493image
ENSG00000125741.4,OPA3PCPGEAGMacrophages_M06.0475e-040.2525image
chr19:45548988-45551287:-PRADEERB_cells_naive1.3305e-040.1712image
ENSG00000125741.4,OPA3PRADEAGB_cells_naive3.9101e-040.1591image
chr19:45548988-45551287:-READEERNK_cells_resting3.2068e-020.2249image
ENSG00000125741.4,OPA3READEAGNK_cells_resting3.5892e-020.2203image
chr19:45548988-45551287:-SARCEERB_cells_memory3.9069e-02-0.1293image
ENSG00000125741.4,OPA3SARCEAGB_cells_memory4.5949e-02-0.1251image
chr19:45548988-45551287:-SKCMEERT_cells_gamma_delta9.3795e-030.1196image
ENSG00000125741.4,OPA3SKCMEAGT_cells_gamma_delta4.7717e-030.1298image
chr19:45548988-45551287:-STADEERT_cells_follicular_helper3.4588e-030.1554image
ENSG00000125741.4,OPA3STADEAGT_cells_follicular_helper9.1516e-030.1384image
chr19:45548988-45551287:-TGCTEERMacrophages_M21.1424e-02-0.2034image
ENSG00000125741.4,OPA3TGCTEAGMacrophages_M21.8550e-02-0.1896image
chr19:45548988-45551287:-THCAEERT_cells_gamma_delta1.0739e-020.1137image
ENSG00000125741.4,OPA3THCAEAGT_cells_regulatory_(Tregs)8.7946e-030.1167image
chr19:45548988-45551287:-THYMEERPlasma_cells1.5672e-030.2880image
ENSG00000125741.4,OPA3THYMEAGPlasma_cells3.7729e-030.2647image
chr19:45548988-45551287:-UCSEEREosinophils4.0928e-020.2741image
ENSG00000125741.4,OPA3UCSEAGEosinophils3.8591e-020.2772image
chr19:45548988-45551287:-UVMEERT_cells_CD4_memory_resting7.9474e-03-0.2948image
ENSG00000125741.4,OPA3UVMEAGMast_cells_resting8.1251e-03-0.2940image


Top

6. Enriched editing regions and immune gene sets for OPA3


all structure

check button Correlation of enriched editing regions with epithelial-mesenchymal transition.
* First, the differences of enriched editing regions between Epi and Mes groups (defined by KS-test) were compared (P<0.05 and Informative number >=20).
* Second, the correlations between enriched editing regions and gene set score of HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly edited between Epi and Mes group.
ID_eventscancerTypeE2M_PBoxplotCorPCorRCorrelationPlot


Top

check button Correlations of enriched editing regions with hypoxic.
* First, there are four hypoxia scores used in the database. The first three hypoxic scores were calculated on three gene sets of Buffa, Ragnum and Winter based on one previous study (PMID: 32024819). One last hypoxia score was defined on HALLMARK_HYPOXIA by GSVA method.
* Second, the correlations enriched editing regions with the four hypoxic scores were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly correlated with all four hypoxia gene set scores. For more results, please go to download page.
ID_eventscancerTypeBuffa_P Buffa_R Ragnum_P Ragnum_R Winter_P Winter_R HALLMARK_P HALLMARK_R CorrelationPlot


Top

check button Associations of enriched editing regions with hallmark gene sets from MSigDB.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerHallmarkTypeTypePRCorrelationPlot
chr19:45552272-45552892:-BRCAGSVA_HALLMARK_MITOTIC_SPINDLEEER1.4213e-05-0.2807image
chr19:45548988-45551287:-BRCAGSVA_HALLMARK_ESTROGEN_RESPONSE_LATEEER9.0493e-040.1011image
ENSG00000125741.4,OPA3BRCAGSVA_HALLMARK_ESTROGEN_RESPONSE_LATEEAG1.3213e-040.1162image
ENSG00000125741.4,OPA3CHOLGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG4.4306e-020.3420image
chr19:45548988-45551287:-CHOLGSVA_HALLMARK_SPERMATOGENESISEER3.3489e-020.3603image
ENSG00000125741.4,OPA3COADGSVA_HALLMARK_HEME_METABOLISMEAG1.9135e-020.1478image
chr19:45548988-45551287:-COADGSVA_HALLMARK_HEME_METABOLISMEER4.3712e-030.1793image
chr19:45548988-45551287:-DLBCGSVA_HALLMARK_UV_RESPONSE_DNEER1.8435e-020.3390image
ENSG00000125741.4,OPA3DLBCGSVA_HALLMARK_UV_RESPONSE_DNEAG2.3604e-020.3263image
ENSG00000125741.4,OPA3ESCAGSVA_HALLMARK_BILE_ACID_METABOLISMEAG1.9572e-02-0.1844image
chr19:45548988-45551287:-ESCAGSVA_HALLMARK_BILE_ACID_METABOLISMEER2.4738e-02-0.1775image
chr19:45552272-45552892:-ESCAGSVA_HALLMARK_MITOTIC_SPINDLEEER6.8229e-03-0.2966image
ENSG00000125741.4,OPA3GBMGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEAG7.3108e-03-0.2120image
chr19:45548988-45551287:-GBMGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEER1.2254e-02-0.1982image
ENSG00000125741.4,OPA3HNSCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG3.6537e-030.1301image
chr19:45548988-45551287:-HNSCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER8.2375e-040.1496image
chr19:45548988-45551287:-KIRCGSVA_HALLMARK_UV_RESPONSE_DNEER1.3732e-03-0.1638image
ENSG00000125741.4,OPA3KIRCGSVA_HALLMARK_UV_RESPONSE_DNEAG2.3594e-03-0.1553image
chr19:45548988-45551287:-KIRPGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEER3.7416e-020.1231image
ENSG00000125741.4,OPA3KIRPGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEAG2.9255e-020.1289image
ENSG00000125741.4,OPA3LAMLGSVA_HALLMARK_KRAS_SIGNALING_DNEAG1.4352e-020.2361image
chr19:45548988-45551287:-LGGGSVA_HALLMARK_KRAS_SIGNALING_DNEER3.0864e-04-0.1596image
ENSG00000125741.4,OPA3LGGGSVA_HALLMARK_KRAS_SIGNALING_DNEAG2.1548e-04-0.1636image
chr19:45548988-45551287:-LIHCGSVA_HALLMARK_BILE_ACID_METABOLISMEER1.7801e-090.3079image
ENSG00000125741.4,OPA3LIHCGSVA_HALLMARK_BILE_ACID_METABOLISMEAG4.3164e-100.3188image
chr19:45548988-45551287:-LUADGSVA_HALLMARK_UV_RESPONSE_UPEER3.3903e-030.1332image
ENSG00000125741.4,OPA3LUADGSVA_HALLMARK_UV_RESPONSE_UPEAG2.4492e-020.1023image
ENSG00000125741.4,OPA3LUSCGSVA_HALLMARK_HEDGEHOG_SIGNALINGEAG1.6658e-04-0.1691image
chr19:45548988-45551287:-LUSCGSVA_HALLMARK_HEDGEHOG_SIGNALINGEER1.7703e-04-0.1686image
chr19:45548988-45551287:-MESOGSVA_HALLMARK_TGF_BETA_SIGNALINGEER1.2873e-02-0.2736image
ENSG00000125741.4,OPA3MESOGSVA_HALLMARK_CHOLESTEROL_HOMEOSTASISEAG7.3480e-03-0.2940image
chr19:45552272-45552892:-OVGSVA_HALLMARK_UV_RESPONSE_DNEER2.5647e-05-0.3849image
ENSG00000125741.4,OPA3OVGSVA_HALLMARK_MITOTIC_SPINDLEEAG5.1915e-09-0.3378image
chr19:45548988-45551287:-OVGSVA_HALLMARK_HEDGEHOG_SIGNALINGEER5.6004e-09-0.3371image
ENSG00000125741.4,OPA3PAADGSVA_HALLMARK_HEDGEHOG_SIGNALINGEAG4.0132e-02-0.1544image
ENSG00000125741.4,OPA3PCPGGSVA_HALLMARK_PI3K_AKT_MTOR_SIGNALINGEAG2.6002e-02-0.1655image
chr19:45548988-45551287:-PCPGGSVA_HALLMARK_PI3K_AKT_MTOR_SIGNALINGEER4.0032e-02-0.1528image
chr19:45548988-45551287:-PRADGSVA_HALLMARK_XENOBIOTIC_METABOLISMEER1.4962e-03-0.1426image
ENSG00000125741.4,OPA3PRADGSVA_HALLMARK_XENOBIOTIC_METABOLISMEAG8.7808e-04-0.1494image
chr19:45548988-45551287:-READGSVA_HALLMARK_ALLOGRAFT_REJECTIONEER2.8988e-030.3088image
ENSG00000125741.4,OPA3READGSVA_HALLMARK_ALLOGRAFT_REJECTIONEAG3.3124e-030.3048image
chr19:45548988-45551287:-SARCGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATIONEER2.1336e-02-0.1441image
ENSG00000125741.4,OPA3SARCGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATIONEAG2.6994e-02-0.1385image
ENSG00000125741.4,OPA3SKCMGSVA_HALLMARK_BILE_ACID_METABOLISMEAG1.2974e-02-0.1144image
chr19:45548988-45551287:-SKCMGSVA_HALLMARK_ANGIOGENESISEER1.5589e-02-0.1114image
chr19:45552272-45552892:-STADGSVA_HALLMARK_MITOTIC_SPINDLEEER5.5873e-05-0.2989image
chr19:45548988-45551287:-STADGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER2.1966e-060.2492image
ENSG00000125741.4,OPA3STADGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG1.5381e-050.2276image
chr19:45548988-45551287:-TGCTGSVA_HALLMARK_NOTCH_SIGNALINGEER8.1781e-03-0.2124image
ENSG00000125741.4,OPA3TGCTGSVA_HALLMARK_NOTCH_SIGNALINGEAG1.7951e-02-0.1905image
ENSG00000125741.4,OPA3THCAGSVA_HALLMARK_ANGIOGENESISEAG2.9877e-02-0.0968image
chr19:45548988-45551287:-THCAGSVA_HALLMARK_ANGIOGENESISEER2.6502e-02-0.0989image
chr19:45548988-45551287:-THYMGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEER4.8185e-02-0.1823image
ENSG00000125741.4,OPA3THYMGSVA_HALLMARK_SPERMATOGENESISEAG4.4550e-02-0.1853image
ENSG00000125741.4,OPA3UCECGSVA_HALLMARK_DNA_REPAIREAG5.1579e-03-0.2124image
chr19:45548988-45551287:-UCECGSVA_HALLMARK_DNA_REPAIREER6.5180e-03-0.2067image
chr19:45548988-45551287:-UCSGSVA_HALLMARK_ADIPOGENESISEER4.9466e-03-0.3705image
ENSG00000125741.4,OPA3UCSGSVA_HALLMARK_ADIPOGENESISEAG5.5237e-03-0.3661image
ENSG00000125741.4,OPA3UVMGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG4.4950e-020.2248image
chr19:45548988-45551287:-UVMGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER3.3545e-020.2380image


Top

7. Enriched editing regions and drugs for OPA3


all structure

check button Correlations between enriched editing regions and drug sensitivity.
* First, the drug sensitivity (IS50) was estimated on 84 drugs by pRRophetic package.
* Second, the correlations between editing enriched regions and drug sensitivity were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the IS50 scores of 84 drugs according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerDrugTypePRCorrelationPlot
ENSG00000125741.4,OPA3ACCJNK.9LEAG2.0413e-030.3484image
chr19:45548988-45551287:-ACCJNK.9LEER1.8869e-030.3509image
ENSG00000125741.4,OPA3BLCAGW843682XEAG2.7813e-020.1097image
chr19:45548988-45551287:-BLCAGW843682XEER2.8391e-020.1096image
chr19:45548988-45551287:-BRCAMidostaurinEER3.8848e-040.1081image
ENSG00000125741.4,OPA3BRCAJNK.9LEAG7.6862e-040.1024image
chr19:45552272-45552892:-BRCACEP.701EER8.9238e-04-0.2167image
ENSG00000125741.4,OPA3CESCCHIR.99021EAG1.3711e-030.1834image
chr19:45548988-45551287:-CESCCHIR.99021EER1.1030e-030.1869image
chr19:45548988-45551287:-CHOLGSK.650394EER2.8092e-020.3713image
ENSG00000125741.4,OPA3CHOLCytarabineEAG4.8971e-020.3353image
ENSG00000125741.4,OPA3COADFTI.277EAG7.4459e-04-0.2115image
chr19:45548988-45551287:-COADFTI.277EER5.0982e-04-0.2178image
ENSG00000125741.4,OPA3DLBCBMS.708163EAG3.5745e-03-0.4125image
chr19:45548988-45551287:-DLBCBMS.708163EER2.4307e-03-0.4276image
chr19:45548988-45551287:-ESCAEHT.1864EER4.2753e-020.1604image
chr19:45552272-45552892:-ESCABIRB.0796EER4.9397e-02-0.2178image
ENSG00000125741.4,OPA3ESCABIRB.0796EAG1.7358e-02-0.1879image
ENSG00000125741.4,OPA3GBMBAY.61.3606EAG5.7218e-040.2702image
chr19:45548988-45551287:-GBMBAY.61.3606EER8.2430e-040.2626image
chr19:45548988-45551287:-HNSCBMS.708163EER2.8936e-03-0.1334image
ENSG00000125741.4,OPA3HNSCBMS.708163EAG4.0842e-03-0.1286image
ENSG00000125741.4,OPA3KICHDocetaxelEAG2.1034e-02-0.2857image
ENSG00000125741.4,OPA3KIRCImatinibEAG1.4378e-100.3208image
chr19:45548988-45551287:-KIRCImatinibEER2.6059e-120.3492image
ENSG00000125741.4,OPA3KIRPCamptothecinEAG1.6524e-03-0.1853image
chr19:45548988-45551287:-KIRPCamptothecinEER1.7713e-03-0.1841image
ENSG00000125741.4,OPA3LAMLA.770041EAG1.9131e-02-0.2262image
chr19:45548988-45551287:-LGGAMG.706EER9.5142e-050.1726image
ENSG00000125741.4,OPA3LGGAMG.706EAG1.1219e-040.1709image
ENSG00000125741.4,OPA3LIHCBexaroteneEAG7.4698e-090.2963image
chr19:45548988-45551287:-LIHCBexaroteneEER1.3678e-080.2913image
chr19:45548988-45551287:-LUADAZD.2281EER3.1507e-03-0.1351image
ENSG00000125741.4,OPA3LUADAZD.2281EAG2.6459e-03-0.1373image
ENSG00000125741.4,OPA3LUSCBX.795EAG1.1817e-030.1460image
chr19:45548988-45551287:-LUSCBX.795EER1.4396e-030.1436image
ENSG00000125741.4,OPA3MESOKU.55933EAG1.5821e-030.3435image
chr19:45548988-45551287:-MESOKU.55933EER1.8213e-030.3392image
chr19:45548988-45551287:-OVEmbelinEER1.0745e-090.3518image
ENSG00000125741.4,OPA3OVEmbelinEAG1.3859e-100.3689image
chr19:45552272-45552892:-OVAZD6482EER1.2726e-040.3542image
chr19:45548988-45551287:-PAADJNJ.26854165EER1.8415e-020.1770image
ENSG00000125741.4,OPA3PAADJNJ.26854165EAG1.9159e-020.1759image
ENSG00000125741.4,OPA3PCPGCamptothecinEAG2.7471e-02-0.1639image
chr19:45548988-45551287:-PCPGCamptothecinEER3.4431e-02-0.1573image
ENSG00000125741.4,OPA3PRADMethotrexateEAG6.7823e-06-0.2017image
chr19:45548988-45551287:-PRADMethotrexateEER2.5659e-06-0.2106image
ENSG00000125741.4,OPA3READAKT.inhibitor.VIIIEAG6.7314e-03-0.2822image
chr19:45548988-45551287:-READAKT.inhibitor.VIIIEER6.8563e-03-0.2816image
ENSG00000125741.4,OPA3SKCMGSK.650394EAG5.5490e-04-0.1585image
chr19:45548988-45551287:-SKCMBAY.61.3606EER8.6678e-04-0.1530image
chr19:45552272-45552892:-STADAZD6244EER6.6895e-04-0.2540image
chr19:45548988-45551287:-STADAZD6244EER7.4559e-04-0.1789image
ENSG00000125741.4,OPA3STADAZD6244EAG5.3743e-04-0.1831image
chr19:45548988-45551287:-TGCTAUY922EER1.7158e-030.2507image
ENSG00000125741.4,OPA3TGCTAUY922EAG2.9333e-030.2382image
ENSG00000125741.4,OPA3THCAMethotrexateEAG9.0775e-03-0.1172image
chr19:45548988-45551287:-THCAMethotrexateEER6.6879e-03-0.1218image
ENSG00000125741.4,OPA3THYMA.770041EAG3.3539e-03-0.2679image
chr19:45548988-45551287:-THYMFH535EER3.8620e-030.2640image
chr19:45548988-45551287:-UCECA.443654EER6.5122e-030.2067image
ENSG00000125741.4,OPA3UCECGefitinibEAG9.6192e-03-0.1969image
ENSG00000125741.4,OPA3UCSIPA.3EAG2.1234e-02-0.3073image
chr19:45548988-45551287:-UCSIPA.3EER2.2612e-02-0.3043image
ENSG00000125741.4,OPA3UVMFH535EAG1.3213e-020.2760image
chr19:45548988-45551287:-UVMFH535EER1.0995e-020.2829image


Top

check button EAGs targeted by drugs from DrugBank database.
* EAG: EER-associated genes.
EERENSTUniprotIDDrugBankIDDrugDrugType